




GI breakthrough cuts it for biotech

Nick Sas | January 28, 2016, 6:23 am

Share



GI slices through for biotech.

Shares in biotech Holista Colltech received a much-needed kick yesterday after the company updated the market on its “global scientific breakthrough” in the GI levels of white bread.

The company, which develops “natural healthstyle products”, shot to prominence two weeks ago after announcing its breakthrough, with its shares hitting as high as 28¢.

Its value dipped heavily in the days after the announcement, dropping to as low as 9¢ this week, before getting yesterday’s kick, jumping 5.3¢ to 14.5¢, on the back of the update.

The company said it hoped its product – which it claims will produce “clean label white bread” with the lowest GI index ranking in the world – would be on Australian supermarket shelves in October or November.

The company, which has offices in Perth, Malaysia and Switzerland, also revealed it was looking at raising cash in the new year. It had \$490,000 in the bank at September 30.

Holista’s share price spike came on the same day as a lift in the share price of fellow Perth biotech Recce on the back of new lab results.

The company, chaired by former Chemeq chief Graham Melrose, announced its antibiotic had been shown in a laboratory to kill bacteria associated with tuberculosis and gonorrhoea.

Recce listed on the ASX this month at 20¢ and has had a stellar run.

Its shares jumped 3.5¢ to 43¢ after yesterday’s announcement.

The company, based in Bentley’s Technology Park, is 35 per cent controlled by Dr Melrose, who came to prominence last decade on the back of Chemeq, which at one point was valued at \$550 million.

The company collapsed in 2007 owing \$60 million.